换一批
换一批摘要Nonalcoholic fatty liver disease (NAFLD) remains a leading cause of chronic liver disease. In the context of NAFLD, the presence of nonalcoholic steatohepatitis (NASH) portends an adverse prognosis with greater risk of liver fibrosis and cirrhosis. Although liver biopsy is the keystone of patient management in NAFLD, it is also increasingly clear that such evaluation has its limitations. The availability of biochemical markers of NAFLD and NASH has tremendous potential to radically alter management strategies for these conditions, as well as to monitor disease activity. Our article provides an overview of biomarker discovery and selection in the setting of NAFLD and highlights future directions in the field.
更多相关知识
栏目名称
REVIEW
DOI
10.3748/wjg.15.4387
发布时间
2009-11-16
- 浏览86
- 被引7
- 下载0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
